<code id='EF2AAB355B'></code><style id='EF2AAB355B'></style>
    • <acronym id='EF2AAB355B'></acronym>
      <center id='EF2AAB355B'><center id='EF2AAB355B'><tfoot id='EF2AAB355B'></tfoot></center><abbr id='EF2AAB355B'><dir id='EF2AAB355B'><tfoot id='EF2AAB355B'></tfoot><noframes id='EF2AAB355B'>

    • <optgroup id='EF2AAB355B'><strike id='EF2AAB355B'><sup id='EF2AAB355B'></sup></strike><code id='EF2AAB355B'></code></optgroup>
        1. <b id='EF2AAB355B'><label id='EF2AAB355B'><select id='EF2AAB355B'><dt id='EF2AAB355B'><span id='EF2AAB355B'></span></dt></select></label></b><u id='EF2AAB355B'></u>
          <i id='EF2AAB355B'><strike id='EF2AAB355B'><tt id='EF2AAB355B'><pre id='EF2AAB355B'></pre></tt></strike></i>

          Home / explore / leisure time

          leisure time


          leisure time

          author:entertainment    Page View:3
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In